Katherine Stueland

Chief Executive Officer

Katherine Stueland is CEO of Sema4, a patient-centered health intelligence company. Katherine leads the Sema4 team in its mission to transform healthcare by using genomic and clinical data to enable the delivery of precision medicine as the standard of care. She was appointed CEO of Sema4 after serving as President and CEO of GeneDx, a leader in genomic testing and analysis for rare disorders, which was acquired by Sema4 in April 2022.

Katherine has more than 25 years of experience in the healthcare sector, overseeing multiple commercial organizations from start-up to scale-up and leading corporate brand transformations. Katherine’s career has been driven by her passion for how genomics can improve health outcomes and the importance of broadening research to diverse patient populations to advance science and patient care for all.

Prior to leading GeneDx, Katherine was the Chief Commercial Officer of Invitae Corporation, where she established the corporate brand as the company evolved from a private to a public entity with a market capitalization exceeding $6 billion. Before that, she served as Vice President of Communications and Investor Relations at Dendreon, the first company to bring an immuno-oncology product to market.

Katherine holds a Bachelor of Science in English Language and Literature from Miami University in Ohio.

Eric Schadt

President and Chief Research & Development Officer

Eric Schadt, PhD, is the founder of Sema4. Eric currently serves as President and Chief Research & Development Officer, with responsibility for leading Sema4’s data/informatics, science, and medical functions, advancing its genomic testing solutions, and further evolving its information platform for use in pharma and health system partnerships.

Eric served as CEO of Sema4 for five years. He oversaw rapid growth, driven by the company’s dedication to advancing healthcare through data-driven insights. Among other things, Eric presided over Sema4 as it became a public company trading on Nasdaq in July 2021. After Sema4 acquired GeneDx in April 2022, he transitioned to fully driving R&D. Eric saw a partner in Katherine Stueland, former President & CEO of GeneDx and now CEO of Sema4, who brings extensive commercial and operational experience, allowing him to focus on R&D, his biggest passion.

Eric is a world-renowned expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and Sema4) to elucidate the complexity of human diseases. He has published more than 500 peer-reviewed papers in leading scientific journals (with an h-index > 135) and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis^®, Sema4’s innovative health intelligence platform, Eric is using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Eric is also the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at Icahn School of Medicine at Mount Sinai. He was previously Founding Director of Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.

Eric earned his PhD from the University of California, Los Angeles, his MA from the University of California, Davis, and his BS from California Polytechnic State University-San Luis Obispo.

Isaac Ro

Chief Financial Officer

Isaac Ro has 20 years of financial leadership and experience, with a strong focus on the medical technology and life sciences space. As Chief Financial Officer (CFO) at Sema4, Isaac is responsible for leading all aspects of financial strategy, management, and planning.

Prior to joining Sema4, Isaac served as CFO of Thrive Earlier Detection Corp., a company dedicated to incorporating earlier detection of cancer into routine medical care. In this capacity, he led the sale of Thrive to Exact Sciences Corp. (Nasdaq: EXAS) for $2.15 billion after rapidly scaling the company and raising $257 million in a Series B financing.

Before Thrive, Isaac led the U.S. Medical Technology team at Goldman Sachs where he covered the Life Science Tools, Diagnostics, and Medical Technology sectors. He also held a similar role at SVB Leerink. His career as an equity analyst spanned 16 years, over 60 publicly traded companies, and numerous IPOs and equity financing transactions.

Isaac also serves on the Board of Directors for BioCT.

He holds a BA in History and was pre-med at Middlebury College.

Jennifer Brendel

Chief Commercial Officer

Jennifer (Jen) Brendel has had the privilege of working in life sciences for more than two decades across numerous aspects of healthcare, including prescription + over-the-counter medicines, devices, and diagnostics. She has held leadership roles in a variety of areas, including oncology, neurology, women’s health, cardiovascular, and genetics.

As Chief Commercial Officer (CCO) at Sema4, Jen is responsible for accelerating growth in women’s and newborn health, oncology, and pediatrics. Her motivation is the opportunity to impact as many patients and families as possible while building a team culture where everyone can thrive and perform at their best.

Jen joined Sema4 following the acquisition of GeneDx where she served as Chief Growth Officer. There she established the commercial function, including a salesforce expansion, driving 35% growth. Jen’s experience in genetics began at Invitae where she led the marketing organization and launched consumer and clinician advertising and promotional efforts resulting in a 100% increase in conversions.

Before joining Invitae, Jen was at Bayer and part of a core team, which redesigned the North American Consumer Health operating model to return to growth. While at Bayer, she was nominated by her teammates for a global Bayer LIFE award for Leadership. Jen went to Bayer from Pfizer, where she spent ten years on U.S., regional (based in the United Kingdom), and global teams supporting all stages of lifecycle management, including commercial launches, brand maintenance, and loss of exclusivity strategic planning and implementation.

Earlier in her career, Jen worked at global marketing communications firms and was an oncology sales representative for Tap Pharmaceuticals. She earned her BA from the University of Central Florida.

Dan Clark

General Counsel

Daniel E. Clark is a mission-driven advocate with over 15 years of legal experience. As General Counsel for Sema4, Dan oversees all legal and regulatory matters for the company. He also supports Sema4’s academic mission, having worked as a former Lecturer and Research Assistant at the University of Michigan.

Prior to joining Sema4, Dan worked with Eric Schadt, Sema4’s Founder, and the Icahn Institute in a senior legal role to drive next generation research and industry partnerships. He also practiced in New York City with two leading law firms, clerked for a district judge in the Eastern District of New York, and helped found a boutique startup law firm.

Dan graduated with honors from the University of Michigan School of Law and Pomona College, and has travelled internationally as a Thomas J. Watson Fellow.

Kevin Feeley

SVP, Operations and Head of GeneDx

Kevin Feeley has more than 20 years of leadership experience, with a focus on finance and accounting in the healthcare and pharmaceutical space. As SVP, Operations and Head of GeneDx at Sema4, Kevin is responsible for key operational aspects of the company, including lab network operations, supply chain, customer service, and genetic counseling services.

Kevin joined Sema4 after serving as Chief Financial Officer of OPKO Health’s diagnostics division for six years, which includes BioReference Laboratories, Inc. and GeneDx, which was acquired by Sema4 in April 2022. During the COVID-19 pandemic, Kevin led the operational design and execution of BioReference’s sports diagnostic program serving all four major sports leagues in the U.S.

Before that, Kevin was U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years at KPMG LLP, with a focus in the pharmaceutical industry

Kevin is a Certified Public Accountant and holds a BBA in Accounting from James Madison University.

William Oh

Chief Medical Officer

William K. Oh, MD, is an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. As Chief Medical Officer at Sema4, he is responsible for strategy development, scientific collaborations, clinical development programs, and the adoption of our advanced health intelligence offerings in oncology and a broad spectrum of human diseases.

Before joining Sema4, William served as Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai. He was also the Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at Mount Sinai. In addition to his current role at Sema4, William continues to care for his patients as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai, where he has been recognized by New York Magazine as a Best Doctor for the past decade.

Prior to joining Mount Sinai, William served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center. In addition to his roles as a widely respected clinician, researcher, and principal investigator of multiple clinical trials, William developed large clinical databases and specimen biorepositories for genitourinary cancers at both Harvard’s Dana-Farber Cancer Institute and Mount Sinai.

William has authored more than 300 articles, reviews, and book chapters related to prostate, renal, bladder, and testicular cancers.  He has also edited three books on prostate cancer, and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer.

William is a graduate of Yale College and New York University School of Medicine, and completed his training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

Tony Prentice

Chief Product Officer

Tony Prentice is an innovative product developer, strategist, and leader with extensive experience building and running product, marketing, and partnership organizations. His career spans multiple industries including big data, healthcare, mobile applications, customer experience, financial services, and consumer products.

As Sema4’s Chief Product Officer, Tony is responsible for the strategy and execution of all product-related activities including our patient apps, provider apps, information products for health systems and pharma, clinical software, and new product development of our genomic solutions in Oncology and Women’s Health.

Prior to joining Sema4, Tony served as the Vice President of Mobile Payments at American Express, where he built the organization for new commerce products, applications, and mobile wallets. The team delivered enterprise strategy and products including Apple Pay, Android Pay, and the Amex app.

Previously, Tony held other senior product management roles at American Express for Gold Card, Starwood, Hilton and Blue cards. Before American Express, Tony had various product, general manager, and engineering roles at Starbucks, McKinsey & Company, and General Electric.

Kareem Saad

Chief Transformation Officer

As Chief Transformation Officer at Sema4, Kareem Saad is responsible for strategic initiatives, corporate and business development, and emerging business activities, including overall responsibility for the company’s health system and biopharma business units. Kareem has also served as Chief Business Officer and Chief Strategy Officer at Sema4.

Prior to joining Sema4, Kareem was President and Chief Operating Officer at Apervita, Inc., overseeing its transformation to a product- and value-based care and quality measurement technology company. Kareem previously served as Chief Commercial Officer/EVP of Strategy and Business Development at SourceMed, a PE-backed healthcare IT and services company focused on delivering practice management technology solutions to the outpatient market, where he led a series of transactions that culminated in the sale and merger of the company with Surgical Information Systems.

Kareem also served as a Director in Dell’s Healthcare and Life Sciences division, where he was responsible for managing a $180 million healthcare partner program. Before that, he held a number of executive roles in biotech and healthcare technology startups, as well as leading the Information Based Medicine Commercial Group at IBM’s Healthcare Life Sciences group helping grow that business to $100 million in less than five years.

Kareem holds a BS in Biochemistry and Molecular Biology with a minor in Computer Science from the University of British Columbia and an MBA with a concentration in Economics and Finance from the University of Chicago.

Karen White

Chief People Officer

Karen has more than 25 years of experience in strategy, organization, and leadership development, and human resources, including a decade in the healthcare and life sciences industry. At Sema4, she is responsible for all elements of the people strategy, with a particular focus on talent, diversity, culture, and employee experience.

Prior to joining Sema4 in September 2020, Karen was Vice President of Human Resources for Commercial Solutions at Syneos Health, a fully integrated biopharmaceutical solutions organization. Among other things, she led the Global Commercial team through a merger and transition to processes as a public company. Prior to joining Syneos Health, she has held senior HR roles at other companies in the healthcare space, including inVentiv Health Consulting and Memorial Sloan Kettering Cancer Center. Before that, Karen held positions at large global organizations such as Goldman Sachs, IBM, and PricewaterhouseCoopers.

Karen has a collaborative and flexible approach to designing and delivering high performance solutions. She is a certified executive coach who has designed and implemented groundbreaking development programs to stimulate leadership and improve cultures, and is certified in an array of assessment instruments. Karen has two children and is also an active member of the Leukemia & Lymphoma Society. She earned her MBA from The George Washington University and her BA from Hobart and William Smith Colleges.